JP2011523643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523643A5 JP2011523643A5 JP2011510067A JP2011510067A JP2011523643A5 JP 2011523643 A5 JP2011523643 A5 JP 2011523643A5 JP 2011510067 A JP2011510067 A JP 2011510067A JP 2011510067 A JP2011510067 A JP 2011510067A JP 2011523643 A5 JP2011523643 A5 JP 2011523643A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- item
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- -1 N-methyl-piperazino Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000005647 linker group Chemical group 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 26
- 239000002105 nanoparticle Substances 0.000 description 23
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 239000003118 drug derivative Substances 0.000 description 18
- 125000005842 heteroatom Chemical group 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 10
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000005103 alkyl silyl group Chemical group 0.000 description 3
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 description 3
- 125000005347 halocycloalkyl group Chemical group 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- LWXIHPKOLTXDET-BYPYZUCNSA-N (2s)-2-(2-aminoethylamino)propanoic acid Chemical group OC(=O)[C@H](C)NCCN LWXIHPKOLTXDET-BYPYZUCNSA-N 0.000 description 1
- OHENVLLVUMQCNT-UHFFFAOYSA-N 2-(aminomethylamino)acetic acid Chemical group NCNCC(O)=O OHENVLLVUMQCNT-UHFFFAOYSA-N 0.000 description 1
- QZDZEQOMUGMANT-HGRCFPFLSA-N CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C(C(C)([C@H](C[C@H]2OC[C@]22OC(C)=O)O)[C@@H]2[C@@]2(C3)OC(c4ccccc4)=O)=O)O)C3(C)[C@@]12O)=O)OC(CCCN1CCN(C)CC1)=O)c1ccccc1)=O Chemical compound CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C(C(C)([C@H](C[C@H]2OC[C@]22OC(C)=O)O)[C@@H]2[C@@]2(C3)OC(c4ccccc4)=O)=O)O)C3(C)[C@@]12O)=O)OC(CCCN1CCN(C)CC1)=O)c1ccccc1)=O QZDZEQOMUGMANT-HGRCFPFLSA-N 0.000 description 1
- UQULALZGMRBUMD-FSBDEDPYSA-N CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C([C@](C)([C@H](C[C@H]2OC3)O)[C@H]([C@@H]4OC(c5ccccc5)=O)[C@@]23OC(C)=O)=O)O)C(C)(C)[C@@]14O)=O)OC(CCN1CCCCC1)=O)c1ccccc1)=O Chemical compound CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C([C@](C)([C@H](C[C@H]2OC3)O)[C@H]([C@@H]4OC(c5ccccc5)=O)[C@@]23OC(C)=O)=O)O)C(C)(C)[C@@]14O)=O)OC(CCN1CCCCC1)=O)c1ccccc1)=O UQULALZGMRBUMD-FSBDEDPYSA-N 0.000 description 1
- ORTQFODLPLMDGP-DNCPDDFDSA-N CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C([C@](C)([C@H](C[C@H]2OC3)O)[C@H]([C@@H]4OC(c5ccccc5)=O)[C@@]23OC(C)=O)=O)O)C(C)(C)[C@@]14O)=O)OC(CN1CCOCC1)=O)c1ccccc1)=O Chemical compound CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C([C@](C)([C@H](C[C@H]2OC3)O)[C@H]([C@@H]4OC(c5ccccc5)=O)[C@@]23OC(C)=O)=O)O)C(C)(C)[C@@]14O)=O)OC(CN1CCOCC1)=O)c1ccccc1)=O ORTQFODLPLMDGP-DNCPDDFDSA-N 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5592908P | 2008-05-23 | 2008-05-23 | |
| US61/055,929 | 2008-05-23 | ||
| PCT/IB2009/006532 WO2009141738A2 (en) | 2008-05-23 | 2009-05-26 | Modified drugs for use in liposomal nanoparticles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014043564A Division JP5744267B2 (ja) | 2008-05-23 | 2014-03-06 | リポソームナノ粒子中で使用するための修飾薬物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523643A JP2011523643A (ja) | 2011-08-18 |
| JP2011523643A5 true JP2011523643A5 (enExample) | 2012-07-19 |
| JP5542804B2 JP5542804B2 (ja) | 2014-07-09 |
Family
ID=41340622
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510067A Expired - Fee Related JP5542804B2 (ja) | 2008-05-23 | 2009-05-26 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2014043564A Expired - Fee Related JP5744267B2 (ja) | 2008-05-23 | 2014-03-06 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2014146559A Expired - Fee Related JP5992019B2 (ja) | 2008-05-23 | 2014-07-17 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2016159491A Expired - Fee Related JP6437968B2 (ja) | 2008-05-23 | 2016-08-16 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2018214441A Pending JP2019048851A (ja) | 2008-05-23 | 2018-11-15 | リポソームナノ粒子中で使用するための修飾薬物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014043564A Expired - Fee Related JP5744267B2 (ja) | 2008-05-23 | 2014-03-06 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2014146559A Expired - Fee Related JP5992019B2 (ja) | 2008-05-23 | 2014-07-17 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2016159491A Expired - Fee Related JP6437968B2 (ja) | 2008-05-23 | 2016-08-16 | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2018214441A Pending JP2019048851A (ja) | 2008-05-23 | 2018-11-15 | リポソームナノ粒子中で使用するための修飾薬物 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US8790691B2 (enExample) |
| EP (2) | EP3415151A1 (enExample) |
| JP (5) | JP5542804B2 (enExample) |
| KR (5) | KR101975843B1 (enExample) |
| CN (2) | CN104622809B (enExample) |
| CA (3) | CA2989616A1 (enExample) |
| ES (1) | ES2694481T3 (enExample) |
| IL (2) | IL209419A (enExample) |
| WO (1) | WO2009141738A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104622809B (zh) * | 2008-05-23 | 2019-04-19 | 英属哥伦比亚大学 | 用于脂质体纳米颗粒的修饰的药物 |
| CN102018672B (zh) * | 2010-11-29 | 2013-09-18 | 广州朗圣药业有限公司 | 一种水溶性药物的脂质体冻干组合物及其制备方法 |
| CN102617517B (zh) * | 2011-01-27 | 2015-11-18 | 李勤耕 | 一类新的7,10-o,o-二甲多西紫杉醇衍生物及其应用 |
| US20130302253A1 (en) * | 2011-01-28 | 2013-11-14 | Koninklijke Philips N.V. | Carriers for the local release of hydrophilic prodrugs |
| WO2012166949A1 (en) * | 2011-05-31 | 2012-12-06 | Regents Of The University Of Minnesota | Silicate prodrugs and nanoparticles |
| WO2014058729A1 (en) * | 2012-10-09 | 2014-04-17 | California Institute Of Technology | In vivo and in vitro carbene insertion and nitrene transfer reactions catalyzed by heme enzymes |
| EP2906518A4 (en) | 2012-10-09 | 2016-07-27 | California Inst Of Techn | CYCLES CATALYZED IN VIVO AND IN VITRO OLEFINCYCLOPROPANATION |
| EP2968145A1 (en) * | 2013-03-13 | 2016-01-20 | Mallinckrodt LLC | Modified docetaxel liposome formulations |
| GB201315321D0 (en) * | 2013-08-28 | 2013-10-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction Buffer |
| EP3052508A1 (en) | 2013-09-30 | 2016-08-10 | Danmarks Tekniske Universitet | Silicone chain extender |
| US9399762B2 (en) | 2014-02-18 | 2016-07-26 | California Institute Of Technology | Methods and systems for sulfimidation or sulfoximidation of organic molecules |
| CN105085437B (zh) * | 2014-05-23 | 2018-07-03 | 上海交通大学 | 3-(1-叔丁氧羰酰哌嗪-4-yl)丙酸的两亲性衍生物及其用途 |
| CN104368011B (zh) * | 2014-11-27 | 2017-05-10 | 东南大学 | 一种药物甜菜碱缀合物、其药物组合物及应用 |
| WO2016134066A1 (en) * | 2015-02-17 | 2016-08-25 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
| TWI678213B (zh) * | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
| US20180344644A1 (en) * | 2015-09-21 | 2018-12-06 | Mallinckrodt Llc | Improved stability of liposome formulations and uses thereof |
| GB201521101D0 (en) | 2015-11-30 | 2016-01-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction buffer |
| WO2017106957A1 (en) * | 2015-12-23 | 2017-06-29 | The University Of British Columbia | Lipid-linked prodrugs |
| WO2018160794A1 (en) | 2017-03-01 | 2018-09-07 | Merrimack Pharmaceuticals, Inc. | Epha2-targeted docetaxel -generating liposomes in combination with an agent that impedes regulatory t cell activity for treating cancer |
| CN109422759B (zh) * | 2017-08-22 | 2021-05-04 | 复旦大学 | 小分子修饰的紫杉烷类水溶性前药及其药用用途 |
| CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
| EP4551194A2 (en) * | 2022-07-07 | 2025-05-14 | Nanostar Pharmaceuticals Ltd. | Multilamellar vesicle drug formulation |
| CN117024381B (zh) * | 2023-08-14 | 2025-08-12 | 沈阳药科大学 | 卡巴他赛衍生物及其脂质体制剂 |
| CN118324842B (zh) * | 2024-04-10 | 2025-05-02 | 沈阳药科大学 | 地塞米松弱碱性衍生物及其制剂的制备及应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2979518A (en) * | 1956-08-14 | 1961-04-11 | Organon | New steroid alaninates |
| GB1272841A (en) * | 1969-01-23 | 1972-05-03 | Leo Ab | New corticoid steroid compounds of cytostatic interest |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4443440A (en) * | 1982-08-30 | 1984-04-17 | The Upjohn Company | Amine containing ester prodrugs of corticosteroids |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| DE3587342T2 (de) * | 1984-10-04 | 1993-12-02 | Sandoz Ag | Cyclosporine. |
| US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH01117885A (ja) * | 1987-10-30 | 1989-05-10 | Dai Ichi Seiyaku Co Ltd | 新規ボドフィロトキシン誘導体及びその製造法 |
| ZA886810B (en) * | 1987-12-18 | 1989-08-30 | Bristol Myers Co | Epipodophyllotoxin glucoside 4'-acyl derivatives |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5534632A (en) * | 1991-09-05 | 1996-07-09 | Abbott Laboratories | Macrocyclic carbamate immunomodulators |
| US5457111A (en) * | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
| US5563172A (en) * | 1991-09-05 | 1996-10-08 | Abbott Laboratories | Macrocyclic amide and urea immunomodulators |
| JPH069600A (ja) | 1992-05-06 | 1994-01-18 | Bristol Myers Squibb Co | タクソールのベンゾエート誘導体 |
| US5547981A (en) | 1993-03-09 | 1996-08-20 | Enzon, Inc. | Taxol-7-carbazates |
| US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
| EP0727992A4 (en) | 1993-10-20 | 2001-01-31 | Enzon Inc | SUBSTITUTED TAXOID SUBSTANCES IN 2 'AND / OR 7' POSITION |
| US5489589A (en) | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
| JPH09110865A (ja) * | 1995-08-15 | 1997-04-28 | Masao Oguro | タキソール誘導体 |
| US6107332A (en) | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
| AU714992B2 (en) * | 1996-08-23 | 2000-01-13 | Alza Corporation | Liposomes containing a cisplatin compound |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| CA2369595C (en) * | 1999-04-23 | 2010-10-05 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
| FR2810321B1 (fr) * | 2000-06-20 | 2002-07-26 | Adir | Nouveaux derives de podophyllotoxine carbamate et thiocarbamate, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1323415B1 (en) * | 2000-10-04 | 2010-01-13 | Kyowa Hakko Kirin Co., Ltd. | Method of coating fine particle with lipid film |
| US6403604B1 (en) * | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US6855720B2 (en) * | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| JP2005500988A (ja) | 2001-03-23 | 2005-01-13 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | 脂肪族アミン薬物複合体 |
| JP2004524368A (ja) * | 2001-03-27 | 2004-08-12 | フェアーズ ファーマシューティカル リサーチ エヌ．ヴェー． | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
| GB0111279D0 (en) * | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
| ITMI20020148A1 (it) * | 2002-01-29 | 2003-07-29 | Nicox Sa | Nuovi corticosteroidi |
| US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
| JP2006508126A (ja) * | 2002-11-06 | 2006-03-09 | アザヤ セラピューティクス インコーポレイティッド | 薬学的製剤のタンパク質安定化されたリポソーム製剤 |
| US7342114B2 (en) * | 2003-07-01 | 2008-03-11 | California Pacific Medical Center | Podophyllotoxin derivatives |
| US8173840B2 (en) * | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US20050095283A1 (en) | 2003-09-16 | 2005-05-05 | Aphios Corporation | Compositions and methods for topically treating diseases |
| JP2007522094A (ja) | 2003-09-22 | 2007-08-09 | アシドフィル エルエルシー | 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法 |
| EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
| NZ548195A (en) * | 2004-01-14 | 2011-01-28 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| US8932627B2 (en) * | 2004-09-09 | 2015-01-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal compositions of glucocorticoid and glucocorticoid derivatives |
| MX2007005234A (es) * | 2004-10-29 | 2008-03-10 | Neopharm Inc | Proceso de fabricacion para preparaciones liposomales. |
| JP4504845B2 (ja) * | 2005-03-11 | 2010-07-14 | テスコ・エコライティング株式会社 | 照明器具用下部反射板の取り付け具 |
| WO2006117220A2 (en) * | 2005-05-04 | 2006-11-09 | Medigene Ag | Method of administering a cationic liposomal preparation comprising paclitaxel |
| AU2006256518B2 (en) * | 2005-06-09 | 2012-03-15 | Meda Ab | Method and composition for treating inflammatory disorders |
| BRPI0708299A2 (pt) * | 2006-02-27 | 2011-05-24 | Univ Leland Stanford Junior | composições e métodos para o transporte de moléculas com propriedades melhoradas de liberação através de barreiras biológicas |
| TWI528976B (zh) * | 2006-12-13 | 2016-04-11 | 斯茹林製藥公司 | 用於醫物傳遞之以環糊精為基之聚合物 |
| CN101029034B (zh) | 2007-03-30 | 2010-05-26 | 浙江大学 | 多烯紫杉醇水溶性衍生物及制备方法和用途 |
| CN104622809B (zh) * | 2008-05-23 | 2019-04-19 | 英属哥伦比亚大学 | 用于脂质体纳米颗粒的修饰的药物 |
-
2009
- 2009-05-26 CN CN201410836670.7A patent/CN104622809B/zh not_active Expired - Fee Related
- 2009-05-26 EP EP18185021.5A patent/EP3415151A1/en not_active Withdrawn
- 2009-05-26 WO PCT/IB2009/006532 patent/WO2009141738A2/en not_active Ceased
- 2009-05-26 JP JP2011510067A patent/JP5542804B2/ja not_active Expired - Fee Related
- 2009-05-26 KR KR1020187032439A patent/KR101975843B1/ko not_active Expired - Fee Related
- 2009-05-26 US US12/993,482 patent/US8790691B2/en not_active Expired - Fee Related
- 2009-05-26 KR KR1020197012513A patent/KR20190049930A/ko not_active Ceased
- 2009-05-26 CA CA2989616A patent/CA2989616A1/en not_active Abandoned
- 2009-05-26 CA CA2910133A patent/CA2910133C/en not_active Expired - Fee Related
- 2009-05-26 ES ES09750195.1T patent/ES2694481T3/es active Active
- 2009-05-26 EP EP09750195.1A patent/EP2282724B1/en not_active Not-in-force
- 2009-05-26 CN CN200980128975.XA patent/CN102105135B/zh not_active Expired - Fee Related
- 2009-05-26 KR KR1020187003893A patent/KR101919093B1/ko not_active Expired - Fee Related
- 2009-05-26 KR KR1020107028838A patent/KR101659457B1/ko not_active Expired - Fee Related
- 2009-05-26 KR KR1020167025450A patent/KR101830018B1/ko not_active Expired - Fee Related
- 2009-05-26 CA CA2725535A patent/CA2725535C/en not_active Expired - Fee Related
-
2010
- 2010-11-18 IL IL209419A patent/IL209419A/en active IP Right Grant
-
2012
- 2012-05-08 US US13/467,021 patent/US8324410B2/en not_active Expired - Fee Related
-
2013
- 2013-04-19 US US13/866,873 patent/US8545876B1/en not_active Expired - Fee Related
- 2013-04-19 US US13/866,956 patent/US8545877B2/en not_active Expired - Fee Related
- 2013-04-19 US US13/866,913 patent/US8568772B2/en not_active Expired - Fee Related
- 2013-04-25 IL IL225961A patent/IL225961A/en active IP Right Grant
-
2014
- 2014-03-06 JP JP2014043564A patent/JP5744267B2/ja not_active Expired - Fee Related
- 2014-06-12 US US14/302,537 patent/US9968554B2/en not_active Expired - Fee Related
- 2014-07-17 JP JP2014146559A patent/JP5992019B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-16 JP JP2016159491A patent/JP6437968B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-09 US US15/948,716 patent/US20180221279A1/en not_active Abandoned
- 2018-11-15 JP JP2018214441A patent/JP2019048851A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523643A5 (enExample) | ||
| Fedorowicz et al. | Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules | |
| Lee et al. | Conjugated chitosan as a novel platform for oral delivery of paclitaxel | |
| Skwarczynski et al. | Paclitaxel prodrugs: toward smarter delivery of anticancer agents | |
| TWI394774B (zh) | Novel block copolymers, microcell modifiers, and anticancer agents that are useful as an active ingredient | |
| Wirth et al. | Azide vs alkyne functionalization in Pt (II) complexes for post-treatment click modification: solid-state structure, fluorescent labeling, and cellular fate | |
| JP2009542716A5 (enExample) | ||
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| CA2583700A1 (en) | Quinone prodrug compositions and methods of use | |
| ES2774662T3 (es) | Derivados de Pt (IV) y nanotransportadores que los comprenden | |
| JP2017531041A5 (enExample) | ||
| CA3145109A1 (en) | Cannabinoid conjugate molecules | |
| MX2007012688A (es) | Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida. | |
| CN107660210B (zh) | 基于硼替佐米的递送系统 | |
| Saleh et al. | Cucurbiturils in drug delivery and for biomedical applications | |
| Wierzba et al. | Synthetic approaches toward vitamin B12 conjugates | |
| WO2014204856A1 (en) | Fatty acid anticancer derivatives and their uses | |
| US20250367312A1 (en) | Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| JP2010535204A5 (enExample) | ||
| US8614228B2 (en) | Quinone prodrug compositions and methods of use | |
| US20200069811A1 (en) | Peptide-based multiple-drug delivery vehicle | |
| JPWO2020094471A5 (enExample) | ||
| CN109563215A (zh) | 聚合物连接子及其用途 | |
| JP2014515354A5 (enExample) |